ReviewCurrent opinion in supportive and palliative care2013
Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment.
Review in Current opinion in supportive and palliative care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysis.Nutrition journal · 2016Pooled it
- Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review.Endocrine-related cancer · 2016Pooled it
- Appetite and food intake results from phase I studies of anamorelin.Journal of cachexia, sarcopenia and muscle · 2019Trial
- Review
- Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options.Frontiers in oncology · 2020Review
- IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.Skeletal muscle · 2019Article
- Appetite, Metabolism and Hormonal Regulation in Normal Ageing and Dementia.Diseases (Basel, Switzerland) · 2018Review
- Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's disease.Scientific reports · 2017Article
- Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia.Scientific reports · 2017Article
- Update on Management of Cancer-Related Cachexia.Current oncology reports · 2017Review
- Ghrelin promotes oral tumor cell proliferation by modifying GLUT1 expression.Cellular and molecular life sciences : CMLS · 2016Article
- Intracerebroventricular urocortin 3 counteracts central acyl ghrelin-induced hyperphagic and gastroprokinetic effects via CRF receptor 2 in rats.Drug design, development and therapy · 2016Article
- Ghrelin administration suppresses inflammation-associated colorectal carcinogenesis in mice.Cancer science · 2015Article
- The Influence of Ghrelin on the Development of Dextran Sodium Sulfate-Induced Colitis in Rats.BioMed research international · 2015Article
- Revisiting Cancer Cachexia: Pathogenesis, Diagnosis, and Current Treatment Approaches.Asia-Pacific journal of oncology nursingReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
purpose of reviewCachexia is a devastating complication of cancer for which there is no approved treatment. Here we review the clinical development of ghrelin and ghrelin mimetics (also known as growth hormone secretagogues or GHS) for cancer cachexia treatment. RECENT
findingsGhrelin, a novel hormone known to increase appetite, lean and fat mass, and growth hormone secretion, is being developed as a therapeutic option for cancer anorexia-cachexia syndrome (CACS). Recent animal studies suggest that it may also decrease inflammation and that some of its effects may be independent of its only known receptor, the GHS receptor-1a.Clinical studies recently have shown that administration of ghrelin or GHS improves appetite and quality of life as assessed by questionnaires. Weight gain, increased food intake and better tolerance to chemotherapy have also been reported. This treatment appears to be safe and well tolerated. SUMMARY: Ghrelin and GHS have the potential to effectively prevent or reverse CACS. Preliminary studies show improvements in weight stabilization and appetite with short-term usage. Further studies are required to fully characterize the role of ghrelin and GHS for the treatment of CACS and to establish the safety of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.